• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

难治性治疗方法:全面综述。

Treatment Approach of Refractory : A Comprehensive Review.

机构信息

Mayo Clinic, Jacksonville, FL, USA.

出版信息

J Prim Care Community Health. 2021 Jan-Dec;12:21501327211014087. doi: 10.1177/21501327211014087.

DOI:10.1177/21501327211014087
PMID:33949229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8114244/
Abstract

is the most common infection in the world and is associated with gastrointestinal and extra-gastrointestinal manifestations, including peptic ulcer disease, gastrointestinal bleeding, and lymphoproliferative disorders. Despite being discovered less than half a century ago, antibiotic resistance, exacerbated by medication non-adherence and inefficacy of proton pump inhibitors, has grown substantially, explaining the rising incidence of refractory infection. In this review, we discuss risk factors, treatment options, surveillance and follow-up, as well as emerging therapies for refractory .

摘要

是世界上最常见的感染之一,与胃肠道和胃肠道外表现有关,包括消化性溃疡病、胃肠道出血和淋巴增生性疾病。尽管这种感染在不到半个世纪前才被发现,但由于药物不依从和质子泵抑制剂无效导致的抗生素耐药性已经大大增加,这解释了难治性感染发病率的上升。在这篇综述中,我们讨论了难治性感染的危险因素、治疗选择、监测和随访,以及新出现的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41f/8114244/4c93fb54c9c0/10.1177_21501327211014087-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41f/8114244/4c93fb54c9c0/10.1177_21501327211014087-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f41f/8114244/4c93fb54c9c0/10.1177_21501327211014087-fig1.jpg

相似文献

1
Treatment Approach of Refractory : A Comprehensive Review.难治性治疗方法:全面综述。
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211014087. doi: 10.1177/21501327211014087.
2
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.质子泵抑制剂在复杂性溃疡疾病和上消化道出血中的应用。
Am J Health Syst Pharm. 1999 Dec 1;56(23 Suppl 4):S5-11. doi: 10.1093/ajhp/56.suppl_4.S5.
3
Diagnosis and Treatment of Peptic Ulcer Disease.消化性溃疡病的诊断与治疗。
Am J Med. 2019 Apr;132(4):447-456. doi: 10.1016/j.amjmed.2018.12.009. Epub 2019 Jan 3.
4
[Peptic ulcer: facts and questions -- 2010].[消化性溃疡:事实与问题——2010年]
Orv Hetil. 2010 Jun 27;151(26):1054-61. doi: 10.1556/OH.2010.28892.
5
Peptic ulcer.消化性溃疡。
Med Clin (Barc). 2023 Sep 29;161(6):260-266. doi: 10.1016/j.medcli.2023.05.008. Epub 2023 Jun 24.
6
[Peptic Ulcer Disease Associated with Helicobacter pylori Infection].[幽门螺杆菌感染相关的消化性溃疡疾病]
Korean J Gastroenterol. 2016 Jun 25;67(6):289-99. doi: 10.4166/kjg.2016.67.6.289.
7
Helicobacter pylori-associated peptic ulcer disease in older patients: current management strategies.老年患者幽门螺杆菌相关性消化性溃疡疾病:当前的管理策略
Drugs Aging. 2001;18(7):487-94. doi: 10.2165/00002512-200118070-00002.
8
[Risk factors for development and recurrence of peptic ulcer disease].[消化性溃疡疾病发生及复发的危险因素]
Korean J Gastroenterol. 2010 Oct;56(4):220-8. doi: 10.4166/kjg.2010.56.4.220.
9
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.幽门螺杆菌感染与服用低剂量阿司匹林的老年患者使用质子泵抑制剂预防消化性溃疡
Dig Liver Dis. 2004 Oct;36(10):666-70. doi: 10.1016/j.dld.2004.05.011.
10
Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.质子泵抑制剂治疗急性上消化道出血的临床疗效及成本效益的系统评价
Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. doi: 10.3310/hta11510.

引用本文的文献

1
Targeting Urease: A Promising Adjuvant Strategy for Effective Eradication.靶向脲酶:一种有望实现有效根除的辅助策略。
ACS Omega. 2025 Jul 4;10(27):28643-28669. doi: 10.1021/acsomega.5c02725. eCollection 2025 Jul 15.
2
Helicobacter pylori in Bahrain: A Comprehensive Study of Patient Characteristics, Treatment Approaches, and Cure Rates.巴林的幽门螺杆菌:患者特征、治疗方法及治愈率的综合研究
Cureus. 2025 Feb 20;17(2):e79341. doi: 10.7759/cureus.79341. eCollection 2025 Feb.
3
Multidisciplinary Approach Improves Eradication Rate and Safety in Refractory Helicobacter pylori Infection.

本文引用的文献

1
: a comprehensive review for primary care providers.为初级保健提供者提供的全面综述。
Rom J Intern Med. 2021 May 8;59(2):112-118. doi: 10.2478/rjim-2020-0043. Print 2021 Jun 1.
2
AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.AGA 临床实践更新:难治性幽门螺杆菌感染的管理:专家综述。
Gastroenterology. 2021 Apr;160(5):1831-1841. doi: 10.1053/j.gastro.2020.11.059. Epub 2021 Jan 29.
3
Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy.
多学科方法提高难治性幽门螺杆菌感染的根除率及安全性
Clin Transl Gastroenterol. 2025 Feb 1;16(2):e00804. doi: 10.14309/ctg.0000000000000804.
4
Newer Therapies for Refractory Infection in Adults: A Systematic Review.成人难治性感染的新型疗法:一项系统评价。
Antibiotics (Basel). 2024 Oct 12;13(10):965. doi: 10.3390/antibiotics13100965.
5
Real-world evidence of a novel tetravalent immunoglobulin Y effectiveness and safety in patients with the refractory Helicobacter pylori infection.新型免疫球蛋白 Y 在难治性幽门螺杆菌感染患者中的真实世界疗效和安全性证据。
BMC Infect Dis. 2024 Jun 27;24(1):647. doi: 10.1186/s12879-024-09498-4.
6
The Role of Probiotics in the Eradication of Helicobacter pylori and Overall Impact on Management of Peptic Ulcer: A Study Involving Patients Undergoing Triple Therapy in Bangladesh.益生菌在根除幽门螺杆菌中的作用及对消化性溃疡治疗的总体影响:一项针对孟加拉国接受三联疗法患者的研究
Cureus. 2024 Mar 16;16(3):e56283. doi: 10.7759/cureus.56283. eCollection 2024 Mar.
7
Treatment of infection and gastric ulcer: Need for novel Pharmaceutical formulation.感染与胃溃疡的治疗:新型药物制剂的需求
Heliyon. 2023 Sep 24;9(10):e20406. doi: 10.1016/j.heliyon.2023.e20406. eCollection 2023 Oct.
8
Drug-Resistant : Diagnosis and Evidence-Based Approach.耐药性:诊断与循证方法
Diagnostics (Basel). 2023 Sep 14;13(18):2944. doi: 10.3390/diagnostics13182944.
9
Current paradigms in the management of refractory Helicobacter pylori infection.难治性幽门螺杆菌感染的当前管理范式。
Indian J Gastroenterol. 2023 Dec;42(6):766-779. doi: 10.1007/s12664-023-01448-3. Epub 2023 Sep 22.
10
Unpacking the Racial Gap: Helicobacter pylori Infection Clearance Among Different Racial Groups.剖析种族差异:不同种族群体中幽门螺杆菌感染的清除情况
Cureus. 2023 Aug 7;15(8):e43080. doi: 10.7759/cureus.43080. eCollection 2023 Aug.
粪便中对克拉霉素和左氧氟沙星的原发性和继发性基因型耐药性检测:意大利南部的4年情况
Antibiotics (Basel). 2020 Oct 21;9(10):723. doi: 10.3390/antibiotics9100723.
4
Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains.利福布汀方案补救治疗对双重耐药菌株所致难治性幽门螺杆菌感染
BMC Gastroenterol. 2020 Jul 10;20(1):218. doi: 10.1186/s12876-020-01370-4.
5
Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.新型含利福布汀三联疗法联合沃诺拉赞治疗难治性幽门螺杆菌感染的疗效和安全性:一项前瞻性单臂研究。
Helicobacter. 2020 Oct;25(5):e12719. doi: 10.1111/hel.12719. Epub 2020 Jun 29.
6
Rifabutin-Based Triple Therapy (RHB-105) for Eradication: A Double-Blind, Randomized, Controlled Trial.利福布丁三联疗法(RHB-105)根除幽门螺杆菌:一项双盲、随机、对照试验。
Ann Intern Med. 2020 Jun 16;172(12):795-802. doi: 10.7326/M19-3734. Epub 2020 May 5.
7
eradication therapy to prevent gastric cancer: systematic review and meta-analysis.根除疗法预防胃癌:系统评价和荟萃分析。
Gut. 2020 Dec;69(12):2113-2121. doi: 10.1136/gutjnl-2020-320839. Epub 2020 Mar 23.
8
Family History of Gastric Cancer and Treatment.胃癌家族史和治疗。
N Engl J Med. 2020 Jan 30;382(5):427-436. doi: 10.1056/NEJMoa1909666.
9
High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis.高克拉霉素耐药率及其对智利圣地亚哥人群幽门螺杆菌根除的影响:队列研究和荟萃分析。
Sci Rep. 2019 Dec 27;9(1):20070. doi: 10.1038/s41598-019-56399-7.
10
AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia.美国胃肠病学会关于胃肠化生管理的临床实践指南
Gastroenterology. 2020 Feb;158(3):693-702. doi: 10.1053/j.gastro.2019.12.003. Epub 2019 Dec 6.